|
US8153646B2
(en)
|
2000-08-10 |
2012-04-10 |
Dart Neuroscience (Cayman) Ltd. |
Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
|
|
US9931318B2
(en)
|
2003-04-08 |
2018-04-03 |
Dart Neuroscience (Cayman) Ltd. |
Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
|
|
RU2340600C2
(ru)
|
2001-10-16 |
2008-12-10 |
Мемори Фармасьютиклз Корпорейшн |
Производные 4-(4-алкокси-3-гидроксифенил)-2-пирролидона в качестве ингибиторов pde-4 для лечения неврологических синдромов
|
|
UA80957C2
(en)
*
|
2001-11-01 |
2007-11-26 |
Sciclone Pharmaceuticals Inc |
Method of administering a thymosin alpha 1 peptide
|
|
US20030220280A1
(en)
*
|
2002-02-07 |
2003-11-27 |
Bunge Mary Bartlett |
Schwann cell bridge implants and phosphodiesterase inhibitors to stimulate CNS nerve regeneration
|
|
US20060153827A1
(en)
*
|
2002-08-15 |
2006-07-13 |
Gruskin Elliott A |
Chimeric protein
|
|
EP1613590A2
(en)
|
2003-04-16 |
2006-01-11 |
Memory Pharmaceutical Corporation |
4-(3,4-disubstituted phenyl)-pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
|
|
JP2006523719A
(ja)
|
2003-04-18 |
2006-10-19 |
メモリー・ファーマシューティカルズ・コーポレイション |
ホスホジエステラーゼ４抑制剤としてのピラゾール誘導体
|
|
EP2460881B1
(en)
*
|
2003-05-16 |
2017-05-03 |
Acorda Therapeutics, Inc. |
Proteoglycan degrading mutants for treatment of CNS
|
|
US7959914B2
(en)
|
2003-05-16 |
2011-06-14 |
Acorda Therapeutics, Inc. |
Methods of reducing extravasation of inflammatory cells
|
|
US20090111812A1
(en)
*
|
2004-06-14 |
2009-04-30 |
Musc Foundation For Research Development |
Methods for treating inflammatory disorders
|
|
WO2006044528A1
(en)
|
2004-10-15 |
2006-04-27 |
Memory Pharmaceuticals Corporation |
Pyrazole derivatives as phosphodiesterase 4 inhibitors
|
|
EP1802615A1
(en)
|
2004-10-20 |
2007-07-04 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
|
US8309057B2
(en)
|
2005-06-10 |
2012-11-13 |
The Invention Science Fund I, Llc |
Methods for elevating neurotrophic agents
|
|
JP5189985B2
(ja)
|
2005-09-26 |
2013-04-24 |
アコーダ セラピューティクス、インク． |
コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
|
|
WO2007048846A1
(de)
*
|
2005-10-27 |
2007-05-03 |
Neuraxo Biopharmaceuticals Gmbh |
Verwendung von eisen chelatisierenden verbindungen, zyklisches adenosinmonophosphat erhöhende verbindungen oder kombinationen davon zur behandlung von axonalen läsionen im zns
|
|
US8927546B2
(en)
*
|
2006-02-28 |
2015-01-06 |
Dart Neuroscience (Cayman) Ltd. |
Therapeutic piperazines
|
|
EP2026813A2
(en)
*
|
2006-05-09 |
2009-02-25 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
SG172602A1
(en)
*
|
2006-05-19 |
2011-07-28 |
Helicon Therapeutics Inc |
Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
|
|
BRPI0814624A2
(pt)
|
2007-07-11 |
2015-01-27 |
Medicinova Inc |
Tratamento de doença neurodegenerativa progresiva com ibudilaste
|
|
US8447409B2
(en)
*
|
2008-10-15 |
2013-05-21 |
Cochlear Limited |
Electroneural interface for a medical implant
|
|
US20140038967A1
(en)
|
2011-03-17 |
2014-02-06 |
Algiax Pharmaceuticals Gmbh |
Novel use for imidazotriazinones
|
|
EP2685975A1
(en)
|
2011-03-17 |
2014-01-22 |
Algiax Pharmaceuticals GmbH |
Novel use of benzofuranylsulfonates
|
|
CN106458878B
(zh)
*
|
2014-03-18 |
2018-08-31 |
艾格埃克斯制药有限公司 |
2-氰基-3-环丙基-3-羟基-n-芳基-硫代丙烯酰胺衍生物
|
|
US20210031012A1
(en)
|
2018-01-26 |
2021-02-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
|
WO2020106757A1
(en)
|
2018-11-19 |
2020-05-28 |
Progenity, Inc. |
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|
|
US11707610B2
(en)
|
2019-12-13 |
2023-07-25 |
Biora Therapeutics, Inc. |
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|